News
PASG
0.6599
+1.30%
0.0085
Weekly Report: what happened at PASG last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at PASG last week (1209-1213)?
Weekly Report · 12/16 09:17
Weekly Report: what happened at PASG last week (1202-1206)?
Weekly Report · 12/09 09:16
Insider Sale: 10% owner at $PASG (PASG) Sells 20,903 Shares
Barchart · 12/07 04:18
Optimistic Buy Rating for Passage Bio Driven by Promising PBFT02 Therapy Potential and Accelerated Approval Pathway
TipRanks · 12/02 12:46
Weekly Report: what happened at PASG last week (1125-1129)?
Weekly Report · 12/02 09:16
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/29 21:06
Passage Bio Price Target Announced at $4.00/Share by Wedbush
Dow Jones · 11/29 15:39
Wedbush Assumes Passage Bio at Outperform, Announces Price Target of $4
Benzinga · 11/29 15:30
BUZZ-U.S. STOCKS ON THE MOVE-Prologis, Malibu Boats, Silo Pharma
Reuters · 11/29 14:10
PASSAGE BIO SHARES UP ABOUT 22% AT 81 CENTS PREMARKET AFTER WEDBUSH ASSUMES COVERAGE WITH OUTPERFORM RATING
Reuters · 11/29 13:52
BUZZ-Passage Bio gains as Wedbush assumes coverage with 'outperform' rating
Reuters · 11/29 13:52
Passage Bio assumed with an Outperform at Wedbush
TipRanks · 11/29 11:55
PASSAGE BIO INC <PASG.O>: WEDBUSH ASSUMES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $4 VS $3
Reuters · 11/29 11:37
U.S. RESEARCH ROUNDUP-Applied Therapeutics, Brown-Forman, Ulta Beauty
Reuters · 11/29 11:31
Weekly Report: what happened at PASG last week (1118-1122)?
Weekly Report · 11/25 09:15
Weekly Report: what happened at PASG last week (1111-1115)?
Weekly Report · 11/18 09:14
Passage Bio Price Target Maintained With a $7.00/Share by Chardan Capital
Dow Jones · 11/14 23:01
Passage Bio Is Maintained at Buy by Chardan Capital
Dow Jones · 11/14 23:01
VESTAL POINT CAPITAL LP REPORTS PASSIVE STAKE OF 9.9% IN PASSAGE BIO AS OF SEPTEMBER 30, 2024 - SEC FILING
Reuters · 11/14 17:04
More
Webull provides a variety of real-time PASG stock news. You can receive the latest news about Passage Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.